Immunosyn CEO Hid FDA Hold From Investors, Jury Told

By Diana Novak Jones ( April 19, 2016, 3:32 PM EDT) -- The CEO of publicly traded biopharmaceutical company Immunosyn Corp. hid regulators' concerns about the company's only drug from investors in an effort to keep its stock price high, the U.S. Securities and Exchange Commission told a jury in Illinois federal court Tuesday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!